Disease · MONDO_0005091

severe acute respiratory syndrome

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. severe acute respiratory syndrome. Diseases, record MONDO_0005091. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0005091

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: severe acute respiratory syndrome; Open Targets
Open Targets ID: MONDO_0005091; Open Targets
Other names: Respiratory Syndrome, Acute, Severe, Respiratory Syndrome, Severe Acute, SARS, SARS ASSOC CORONAVIRUS, SARS coronavirus caused disease or disorder, SARS coronavirus disease or disorder, SARS coronavirus infectious disease, SARS-CoV infection, SARS-associated coronavirus, Severe acute respiratory syndrome (disorder), acute respiratory coronavirus infection; Open Targets
Disease Ontology: DOID:2945; Disease Ontology
MeSH: D045169; MeSH
NCI Thesaurus: C85064; NCI Thesaurus
Orphanet: ORPHA:140896; Orphanet
Highest stage of its drugs: Phase 2/3, for 1 of its 11 drugs, from ClinicalTrials.gov; Open Targets

Drugs11

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
PYRIDOSTIGMINE	CHEMBL1115	Small molecule	Phase 2/3	ClinicalTrials.gov	1	1	1	Drugs and targets
METFORMIN GLYCINATE	CHEMBL2108299		Phase 2	ClinicalTrials.gov	2	2	2	Drugs and targets
RUXOLITINIB	CHEMBL1789941	Small molecule	Phase 2	ClinicalTrials.gov	2	2	2	Drugs and targets
CHLOROQUINE PHOSPHATE	CHEMBL58510	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
MARAVIROC	CHEMBL256907	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
METHYLPREDNISOLONE SODIUM SUCCINATE	CHEMBL1201081	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
IBUPROFEN	CHEMBL521	Small molecule	Unknown	ClinicalTrials.gov	1	1	1	Drugs and targets
LOPINAVIR	CHEMBL729	Small molecule	Unknown	ClinicalTrials.gov	1	1	1	Drugs and targets
METHYLPREDNISOLONE	CHEMBL650	Small molecule	Unknown	ClinicalTrials.gov	1	1	1	Drugs and targets
RIBAVIRIN	CHEMBL1643	Small molecule	Unknown	ClinicalTrials.gov	1	1	1	Drugs and targets

1 to 10 of 11

See all 11 drugs

Targets14

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
NR3C1	Glucocorticoid receptor	2	Glucocorticoid receptor agonist	Phase 2	https://conductscience.org/library/genes/2908	Drugs and targets
ACHE	Acetylcholinesterase	1	Acetylcholinesterase inhibitor	Phase 2/3	https://conductscience.org/library/genes/43	Drugs and targets
CCR5	C-C chemokine receptor type 5	1	C-C chemokine receptor type 5 antagonist	Phase 2	https://conductscience.org/library/genes/1234	Drugs and targets
CYP3A4	Cytochrome P450 3A	1	Cytochrome P450 3A inhibitor	Unknown	https://conductscience.org/library/genes/1576	Drugs and targets
CYP3A43	Cytochrome P450 3A	1	Cytochrome P450 3A inhibitor	Unknown	https://conductscience.org/library/genes/64816	Drugs and targets
CYP3A5	Cytochrome P450 3A	1	Cytochrome P450 3A inhibitor	Unknown	https://conductscience.org/library/genes/1577	Drugs and targets
CYP3A7	Cytochrome P450 3A	1	Cytochrome P450 3A inhibitor	Unknown	https://conductscience.org/library/genes/1551	Drugs and targets
IMPDH1	Inosine-5'-monophosphate dehydrogenase 1	1	Inosine-5'-monophosphate dehydrogenase 1 inhibitor	Unknown	https://conductscience.org/library/genes/3614	Drugs and targets
JAK1	Tyrosine-protein kinase JAK1	1	Tyrosine-protein kinase JAK1 inhibitor	Phase 2	https://conductscience.org/library/genes/3716	Drugs and targets
JAK2	Tyrosine-protein kinase JAK2	1	Tyrosine-protein kinase JAK2 inhibitor	Phase 2	https://conductscience.org/library/genes/3717	Drugs and targets

1 to 10 of 14

See all 14 targets

Trials11

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT04323592	Methylprednisolone for Patients With COVID-19 Severe Acute Respiratory Syndrome		173	2020-06-04	Severe Acute Respiratory Syndrome (SARS) Pneumonia, Coronavirus Infections, ARDS, Human	METHYLPREDNISOLONE	Its record names the disease	ClinicalTrials.gov
NCT04343963	Pyridostigmine in Severe SARS-CoV-2 Infection	Phase 2/3	436		COVID-19, SARS-CoV-2	PYRIDOSTIGMINE	Its record names the disease	ClinicalTrials.gov
NCT04343729	Methylprednisolone in the Treatment of Patients With Signs of Severe Acute Respiratory Syndrome in Covid-19	Phase 2	416		SARS-CoV Infection, Severe Acute Respiratory Syndrome (SARS) Pneumonia	METHYLPREDNISOLONE SODIUM SUCCINATE	Its record names the disease	ClinicalTrials.gov
NCT00578825	A Multi-centre, Double-blinded, Randomized, Placebo-controlled Trial on the Efficacy and Safety of Lopinavir / Ritonavir Plus Ribavirin in the Treatment of Severe Acute Respiratory Syndrome	Not applicable	340		Severe Acute Respiratory Syndrome	LOPINAVIR, RIBAVIRIN, RITONAVIR	Its record names the disease	ClinicalTrials.gov
NCT04323527	Chloroquine Diphosphate for the Treatment of Severe Acute Respiratory Syndrome Secondary to SARS-CoV2	Phase 2	278		SARS-CoV Infection, Severe Acute Respiratory Syndrome (SARS) Pneumonia	CHLOROQUINE PHOSPHATE	Its record names the disease	ClinicalTrials.gov
NCT04414098	Ruxolitinib in the Treatment of Covid-19	Phase 2	100		COVID-19	RUXOLITINIB	Its record names the disease	ClinicalTrials.gov
NCT04334044	Treatment of SARS Caused by COVID-19 With Ruxolitinib	Phase 1/2	77		COVID-19, Severe Acute Respiratory Syndrome Coronavirus 2	RUXOLITINIB	Its record names the disease	ClinicalTrials.gov
NCT04710199	Trial to Evaluate the Safety and Efficacy of Maraviroc in Patients Hospitalized for Coronavirus Disease 2019 (COVID-19)	Phase 2	44		Virus Diseases	MARAVIROC	Its record names the disease	ClinicalTrials.gov
NCT04382768	Inhaled Ibuprofen to Treat COVID-19	Not applicable	40		Coronavirus Infection, Respiratory Disease, SARS (Disease)	IBUPROFEN	Its record names the disease	ClinicalTrials.gov
NCT04625985	Metformin Glycinate, Treatment of Patients With COVID-19 and Severe Acute Respiratory Syndrome Secondary to SARS-CoV-2.	Phase 2	20		Severe Acute Respiratory Syndrome Coronavirus 2	METFORMIN GLYCINATE	Its record names the disease	ClinicalTrials.gov

1 to 10 of 11

See all 11 trials

Comparisons in its trials6

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
Exposed to Methylprednisolone vs Non-exposed to Methylprednisolone: Endotracheal Intubation (Invasive Mechanical Ventilation)	15 of 83	26 of 90	173	NCT04323592	Trial comparisons
Exposed to Methylprednisolone vs Non-exposed to Methylprednisolone: In-hospital Death Within 28 Days	6 of 83	21 of 90	173	NCT04323592	Trial comparisons
Exposed to Methylprednisolone vs Non-exposed to Methylprednisolone: Composite Primary End-point: Admission to ICU, Need for Invasive Mechanical Ventilation (MV), or All-cause Death by Day 28	19 of 83	40 of 90	173	NCT04323592	Trial comparisons
Exposed to Methylprednisolone vs Non-exposed to Methylprednisolone: deaths from any cause	9 of 83	24 of 90	173	NCT04323592	Trial comparisons
Exposed to Methylprednisolone vs Non-exposed to Methylprednisolone: Admission to Intensive Care Unit (ICU)	15 of 83	27 of 90	173	NCT04323592	Trial comparisons
Exposed to Methylprednisolone vs Non-exposed to Methylprednisolone: serious adverse events	6 of 83	9 of 90	173	NCT04323592	Trial comparisons

Papers from its trials52

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
32419926	RESULT	1	PubMed
31743697	RESULT	1	PubMed
31226023	RESULT	1	PubMed
30414960	RESULT	1	PubMed
30377252	RESULT	1	PubMed
29772761	RESULT	1	PubMed
29541394	RESULT	1	PubMed
23489075	RESULT	1	PubMed
22974412	RESULT	2	PubMed
21832087	RESULT	1	PubMed

1 to 10 of 52

See all 52 papers from its trials

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0005091

GET https://conductscience.org/api/diseases/v1/MONDO_0005091/papers?page=2

API reference For AI assistants